Indeed, in patients with HCC, the combination of AAT and ICI, but not ICI monotherapy (Finn et al., 2019; Yau et al., 2019), outperforms AAT monotherapy (Finn et al., 2020). The gene discussed is SERPINA1; the disease is hepatocellular carcinoma.